

Binding **list of nominees**

In relation to the Annual General Meeting of Shareholders of Koninklijke Philips N.V. (Royal Philips) to be held on May 3, 2018

Nominees for (re-)appointment as members of the **Supervisory Board**

In accordance with Article 19, paragraph 2 of the Articles of Association of the company, the Supervisory Board nominates the following persons for (re-)appointment as members of the Supervisory Board, at the Annual General Meeting of Shareholders 2018 (which nominations are binding).

Orit Gadiesh (1951, Israeli/American)

Ms Gadiesh has been a member of the Supervisory Board since 2014. She is currently also Chairman of Bain & Company and Member of the Foundation Board of the World Economic Forum (WEF). Furthermore, she serves on the Supervisory Board of Renova AG and is a member of the United States Council of Foreign Relations.

Ms Gadiesh is recommended to be re-appointed in view of her experience and the external perspective she brings to the Supervisory Board. In particular her in-depth knowledge of marketing, technological developments and international business, have proven to be valuable in the way she fulfils her role as member of the Supervisory Board and Audit Committee.

The Supervisory Board proposes to re-appoint Ms Gadiesh as a member of the Supervisory Board, in line with the Dutch Corporate Governance Code, for the term of four years (effectively until the end of the Annual General Meeting of Shareholders to be held in 2022).

Paul Stoffels, M.D. (1962, Belgian)

Mr Stoffels is currently Executive Vice President, Chief Scientific Officer, at Johnson & Johnson. He is a member of the Johnson & Johnson Executive Committee and chairs the Johnson & Johnson R&D Management Committee.

Mr Stoffels has in-depth knowledge across the pharmaceutical, medical device and consumer segments and has lead teams to develop transformational new medicines and healthcare solutions. He is recognized as a visionary leader that has fueled innovative science and technology across the healthcare industry.

His expertise will be invaluable in view of Philips' transformation to a company focused on healthcare technology and the development of innovative value-added integrated solutions.

Previously, in his role as Worldwide Chairman, Pharmaceuticals, Mr Stoffels was responsible for advancing the therapeutic pipeline of Janssen Pharmaceutical Companies of Johnson & Johnson. Before that, Mr Stoffels has held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec. He led the development of a number of breakthrough medicines and diagnostics for the treatment of HIV.

Mr Stoffels does not hold any shares in Royal Philips.

The Supervisory Board proposes to appoint Mr Stoffels as a member of the Supervisory Board per August 1, 2018, in line with the Dutch Corporate Governance Code, for the term of four years (effectively until the end of the Annual General Meeting of Shareholders to be held in 2022).

Amsterdam, March 2018

The Supervisory Board

